alendronate has been researched along with Hypercalciuria in 22 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hypercalciuria: Excretion of abnormally high level of CALCIUM in the URINE, greater than 4 mg/kg/day.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Taking into account their medical past, two drugs were possibly involved: either oral alendronate that their mother had received before pregnancy for misdiagnosed osteoporosis or antireflux medications, or both." | 7.83 | Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications? ( Bacchetta, J; Claris, O; Cochat, P; Fouque-Aubert, A; Gerin, M; Jambon, G; Raybaud, C, 2016) |
| "The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia." | 7.78 | Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012) |
| "We report two patients with high-level spinal cord injuries who have developed hypercalciuria after admission to the rehabilitation unit." | 5.35 | Treatment of immobilization hypercalciuria using weekly alendronate in two quadriplegic patients. ( Atalay, A; Turhan, N, 2008) |
| " Taking into account their medical past, two drugs were possibly involved: either oral alendronate that their mother had received before pregnancy for misdiagnosed osteoporosis or antireflux medications, or both." | 3.83 | Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications? ( Bacchetta, J; Claris, O; Cochat, P; Fouque-Aubert, A; Gerin, M; Jambon, G; Raybaud, C, 2016) |
| "The long-term follow-up of our JMC patient has provided insight on therapeutic strategies to control hypercalciuria, on the potential effects of alendronate on FGF23 levels, and on the lack of detectable cardiovascular disease at young adulthood after prolonged exposure to hypercalcemia." | 3.78 | Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia. ( Correa, PH; Ferraz-de-Souza, B; Martin, RM; Mendonca, BB; Onuchic, L, 2012) |
| "5 months of treatment, oral alendronate is associated with a lower fracture rate, improvement in BMD and a decrease in hypercalciuria." | 3.74 | Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective. ( Johari, A; Shah, I, 2007) |
| "Idiopathic hypercalciuria is a metabolic abnormality with various causes and developmental pathways." | 2.55 | [Idiopathic hypercalciuria. Diagnosis and treatment]. ( Butnaru, DV; Gerasimenko, AS; Gorbatenko, VS; Olefir, YV; Shatalova, OV; Yavorskii, AN, 2017) |
| "Osteoporosis is characterized by a reduction in bone mineral density (BMD) ." | 2.47 | [New therapy using bisphosphonate for urolithiasis]. ( Hirose, M; Niimi, K; Yasui, T, 2011) |
| "We report two patients with high-level spinal cord injuries who have developed hypercalciuria after admission to the rehabilitation unit." | 1.35 | Treatment of immobilization hypercalciuria using weekly alendronate in two quadriplegic patients. ( Atalay, A; Turhan, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Eswarakumar, A | 1 |
| Robinson, C | 1 |
| Carpenter, TO | 1 |
| Bacchetta, J | 2 |
| Garnier, C | 1 |
| Olefir, YV | 1 |
| Yavorskii, AN | 1 |
| Butnaru, DV | 1 |
| Shatalova, OV | 1 |
| Gorbatenko, VS | 1 |
| Gerasimenko, AS | 1 |
| Liao, EY | 1 |
| Zhang, ZL | 1 |
| Xia, WB | 1 |
| Lin, H | 1 |
| Cheng, Q | 1 |
| Wang, L | 1 |
| Hao, YQ | 1 |
| Chen, DC | 1 |
| Tang, H | 1 |
| Peng, YD | 1 |
| You, L | 1 |
| He, L | 1 |
| Hu, ZH | 1 |
| Song, CL | 1 |
| Wei, F | 1 |
| Wang, J | 1 |
| Zhang, L | 1 |
| Ábalos-Medina, GM | 1 |
| Fernández Rodríguez, I | 1 |
| del Mar Almagro Ratia, M | 1 |
| Fuentes Ellauri, MA | 1 |
| Assimos, DG | 2 |
| Frick, KK | 1 |
| Asplin, JR | 1 |
| Culbertson, CD | 1 |
| Granja, I | 1 |
| Krieger, NS | 1 |
| Bushinsky, DA | 1 |
| Gerin, M | 1 |
| Jambon, G | 1 |
| Fouque-Aubert, A | 1 |
| Raybaud, C | 1 |
| Cochat, P | 1 |
| Claris, O | 1 |
| Zhang, Y | 1 |
| Shao, J | 1 |
| Wang, Z | 1 |
| Yang, T | 1 |
| Liu, S | 1 |
| Liu, Y | 1 |
| Fan, X | 1 |
| Ye, W | 1 |
| Freundlich, M | 1 |
| Alon, US | 1 |
| Giusti, A | 1 |
| Barone, A | 1 |
| Pioli, G | 1 |
| Girasole, G | 1 |
| Siccardi, V | 1 |
| Palummeri, E | 1 |
| Bianchi, G | 1 |
| Binkley, N | 1 |
| Ringe, JD | 1 |
| Reed, JI | 1 |
| Ljunggren, O | 1 |
| Holick, MF | 1 |
| Minne, HW | 1 |
| Liu, M | 1 |
| Lamotta, A | 1 |
| West, JA | 1 |
| Santora, AC | 1 |
| Arrabal-Polo, MA | 2 |
| Arrabal-Martin, M | 2 |
| Zuluaga-Gomez, A | 2 |
| Yasui, T | 1 |
| Niimi, K | 1 |
| Hirose, M | 1 |
| Iglesias, P | 1 |
| Castro, JC | 1 |
| Abreu, C | 1 |
| Díez, JJ | 1 |
| Onuchic, L | 1 |
| Ferraz-de-Souza, B | 1 |
| Mendonca, BB | 1 |
| Correa, PH | 1 |
| Martin, RM | 1 |
| Arias-Santiago, S | 1 |
| de Haro-Muñoz, T | 1 |
| Lopez-Ruiz, A | 1 |
| Orgaz-Molina, J | 1 |
| Gonzalez-Torres, S | 1 |
| Antoniucci, DM | 1 |
| Sellmeyer, DE | 1 |
| Bilezikian, JP | 1 |
| Palermo, L | 1 |
| Ensrud, KE | 1 |
| Greenspan, SL | 1 |
| Black, DM | 1 |
| Heller, HJ | 1 |
| Zerwekh, JE | 1 |
| Gottschalk, FA | 1 |
| Pak, CY | 1 |
| Shah, I | 1 |
| Johari, A | 1 |
| Atalay, A | 1 |
| Turhan, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporo[NCT00092079] | Phase 3 | 652 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis[NCT00005005] | Phase 2 | 238 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| The Denosumab And Teriparatide Administration Study (DATA)[NCT00926380] | Phase 2 | 94 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00926380)
Timeframe: Baseline and 2 years
| Intervention | percent change (Mean) |
|---|---|
| Denosumab ONLY | 8.3 |
| Teriparatide (Forteo®) ONLY | 9.5 |
| Denosumab and Teriparatide (Forteo®) | 12.9 |
2 reviews available for alendronate and Hypercalciuria
| Article | Year |
|---|---|
[Idiopathic hypercalciuria. Diagnosis and treatment].
Topics: Alendronate; Female; Humans; Hypercalciuria; Male; Mutation; Nephrolithiasis; Receptors, Calcitriol | 2017 |
[New therapy using bisphosphonate for urolithiasis].
Topics: Alendronate; Animals; Bed Rest; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; C | 2011 |
4 trials available for alendronate and Hypercalciuria
| Article | Year |
|---|---|
Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Ca | 2018 |
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Diuretics; Dose-Response | 2009 |
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Double-Blind Met | 2009 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Calcium; Double-Blind Method; Drug | 2007 |
16 other studies available for alendronate and Hypercalciuria
| Article | Year |
|---|---|
Response to report of rickets in twins occurring after maternal bisphosphonate exposure.
Topics: Alendronate; Familial Hypophosphatemic Rickets; Female; Humans; Hypercalciuria; Infant, Newborn; Pre | 2020 |
Response to: Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins.
Topics: Alendronate; Familial Hypophosphatemic Rickets; Female; Humans; Hypercalciuria; Infant, Newborn; Pre | 2020 |
[Mineral and bone disorder associated with Cacchi-Ricci disease].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Calcifediol; Calcium; Drug Th | 2014 |
Re: effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Humans; Hypercalciu | 2013 |
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitriol; C | 2014 |
Re: Persistence of 1,25D-induced hypercalciuria in alendronate treated genetic hypercalciuric stone-forming rats fed a low calcium diet.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Calcium, Dietar | 2014 |
Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications?
Topics: Alendronate; Anti-Ulcer Agents; Bone Density Conservation Agents; Esomeprazole; Female; Humans; Hype | 2016 |
Aqueous extract of pomegranate seed attenuates glucocorticoid-induced bone loss and hypercalciuria in mice: A comparative study with alendronate.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Duodenum; Glucocorticoids; Hypercalciuria; Kidney; L | 2016 |
Bisphosphonates in children with hypercalciuria and reduced bone mineral density.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; C | 2008 |
[Alendronate and resorptive hypercalciuria].
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; C | 2011 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans | 2012 |
Potential effects of alendronate on fibroblast growth factor 23 levels and effective control of hypercalciuria in an adult with Jansen's metaphyseal chondrodysplasia.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Drug Therapy, Combina | 2012 |
Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Fema | 2013 |
Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria.
Topics: Adult; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; | 2007 |
Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Child; Child, Pre | 2007 |
Treatment of immobilization hypercalciuria using weekly alendronate in two quadriplegic patients.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Humans; Hypercalciuria; Immobilization; Male; | 2008 |